Get started
Author

Jacinth K. Fairley

Observed names: J.K. Fairley, Jacinth Fairley, Jacinth K Fairley
Observed institution: Starpharma (Australia)
ORCID: 0000-0001-6380-8929
Observed ORCID: 0000-0001-6380-8929
OpenAlex ID: A5064686529
Virucidal and antiviral activity of astodrimer sodium against SARS-CoV-2 in vitro
2021 · Jeremy R.A. Paull, Graham P. Heery, et al. · Antiviral Research · 46
PDF
Abstract B039: A phase 1/2 study of dendrimer-enhanced (DEP) SN38 (SN38-SPL9111/DEP irinotecan) in patients with advanced solid tumours
2023 · Jia Liu, Anna R Minchom, et al. · Molecular Cancer Therapeutics · 2
1403P Efficacy and safety of dendrimer-enhanced (DEP) cabazitaxel (CTX-SPL9111) in men with metastatic castration-resistant prostate cancer (mCRPC) in a phase I/II trial
2022 · R.H. Jones, D.J. Pinato, et al. · Annals of Oncology · 2
PDF
Efficacy and safety of dendrimer-enhanced (DEP) cabazitaxel (CTX-SPL9111) in advanced esophagogastric cancers in a phase 1/2 trial.
2024 · David James Pinato, Robert Hugh Jones, et al. · Journal of Clinical Oncology
Works count: 4
Citation count: 50
H-index: 2
I10-index: 1
Year
Topic
Type